BMRN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

823.46M

+10.19%

0.926

+0.6%

818.90M

+9.9%

1.258

+11.33%

848.02M

+2.74%

1.303

-9.51%

Estimates Revision

The market is revising Downward the revenue expectations for BioMarin Pharmaceutical Inc. (BMRN) for FY2025, with the revenue forecasts being adjusted by -0.06% over the past three months. During the same period, the stock price has changed by -3.37%.

Revenue Estimates for FY2025

Revise Downward

-0.06%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-17.39%

In Past 3 Month

Stock Price

Go Down

-3.37%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.50 USD with a low forecast of 55.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

4 Hold

0 Sell

Strong Buy

Current: 52.120

Low

55.00

Averages

87.50

High

120.00

Current: 52.120

Low

55.00

Averages

87.50

High

120.00

Leerink

Outperform -> Market Perform

downgrade

$60

2025-12-03

Reason

Leerink

Price Target

$60

2025-12-03

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded BioMarin to Market Perform from Outperform with a $60 price target.

Leerink

Outperform -> Market Perform

downgrade

$82 -> $60

2025-12-03

Reason

Leerink

Price Target

$82 -> $60

2025-12-03

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded BioMarin to Market Perform from Outperform with a price target of $60, down from $82. BioMarin's new leadership has taken decisive actions, including workforce reductions, ending the Roctavian program, restructuring the pipeline, and acquiring Inozyme, which support more credible long-term financial targets, but competitive pressure in achondroplasia and a sizable pipeline gap make future M&A central to the story, leaving uncertainty about whether these steps are enough to drive meaningful upside from here, the analyst tells investors in a research note.

Stifel

Buy -> Hold

downgrade

$73 -> $61

2025-11-06

Reason

Stifel

Price Target

$73 -> $61

2025-11-06

downgrade

Buy -> Hold

Reason

Stifel downgraded BioMarin to Hold from Buy with a price target of $61, down from $73.

Stifel

Paul Matteis

Buy

Hold

downgrade

$73 -> $61

2025-11-06

Reason

Stifel

Paul Matteis

Price Target

$73 -> $61

2025-11-06

downgrade

Buy

Hold

Reason

Stifel analyst Paul Matteis downgraded BioMarin to Hold from Buy with a price target of $61, down from $73. Even from what feels like an "impaired valuation," it is become harder for the firm to see BioMarin significantly outperforming over the next 12 months, barring a takeout, the analyst tells investors. This is due to competitive concerns for Voxzogo, which are "valid" given key opinion leader checks are "concerning," underlying Voxzogo growth trends that "aren't great" even before competition, and the view that the path to actually disproving the bear case is unclear.

Bernstein

Market Perform

downgrade

$95 -> $88

2025-11-03

Reason

Bernstein

Price Target

$95 -> $88

2025-11-03

downgrade

Market Perform

Reason

Bernstein lowered the firm's price target on BioMarin to $88 from $95 and keeps a Market Perform rating on the shares following quarterly results. The firm notes BioMarin delivered an in-line revenue print but missed on EPS due to consensus mis-modeling of AIPR&D for inozyme.

RBC Capital

Sector Perform

maintain

$70 -> $66

2025-10-28

Reason

RBC Capital

Price Target

$70 -> $66

2025-10-28

maintain

Sector Perform

Reason

RBC Capital lowered the firm's price target on BioMarin to $66 from $70 and keeps a Sector Perform rating on the shares. The company reported an in-line quarter given the Voxzogo miss was offset by the base business beat, the analyst tells investors in a research note. On Voxzogo, this is the very first down quarter since launch, and BioMarin notes some seasonality and a somewhat mixed uptake in older US kids, RBC added.

Valuation Metrics

The current forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN.O) is 10.87, compared to its 5-year average forward P/E of 40.15. For a more detailed relative valuation and DCF analysis to assess BioMarin Pharmaceutical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

40.15

Current PE

10.87

Overvalued PE

64.91

Undervalued PE

15.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

70.36

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

191.97

Undervalued EV/EBITDA

-51.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.21

Current PS

0.00

Overvalued PS

7.85

Undervalued PS

4.57

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BMRN News & Events

Events Timeline

No data

News

8.0

12-08NASDAQ.COM

BioMarin Pharmaceutical (BMRN) Offers August 2026 Options

4.0

12-03Benzinga

Uber Expected to Surge by 43%? Check Out 10 Leading Analyst Predictions for Wednesday

4.0

12-03Benzinga

Wayfair Analyst Changes Stance; Check Out Wednesday's Top 5 Downgrades

People Also Watch

Frequently Asked Questions

What is BioMarin Pharmaceutical Inc (BMRN) stock price today?

The current price of BMRN is 52.12 USD — it has decreased -2.23 % in the last trading day.

What is BioMarin Pharmaceutical Inc (BMRN)'s business?

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

What is the price predicton of BMRN Stock?

What is BioMarin Pharmaceutical Inc (BMRN)'s revenue for the last quarter?

BioMarin Pharmaceutical Inc revenue for the last quarter amounts to 776.13M USD, increased 4.08 % YoY.

What is BioMarin Pharmaceutical Inc (BMRN)'s earnings per share (EPS) for the last quarter?

BioMarin Pharmaceutical Inc. EPS for the last quarter amounts to -0.16 USD, decreased -129.09 % YoY.

What changes have occurred in the market's expectations for BioMarin Pharmaceutical Inc (BMRN)'s fundamentals?

How many employees does BioMarin Pharmaceutical Inc (BMRN). have?

BioMarin Pharmaceutical Inc (BMRN) has 3040 emplpoyees as of December 16 2025.

What is BioMarin Pharmaceutical Inc (BMRN) market cap?

Today BMRN has the market capitalization of 10.01B USD.